Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Oct-01-16 | Oct-03-15 | Sep-27-14 | Sep-28-13 | Sep-29-12 | Oct-01-11 | Oct-02-10 | Oct-03-09 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Custom products | | | | 26.3 | 29.7 | 17.8 | 16.8 | |
| Medical | | | | 47.5 | 46.5 | 34.7 | 35.6 | |
| Total revenues [+] | 67.6 | 64.3 | 55.9 | 73.8 | 76.1 | 52.6 | 52.4 | 55.9 |
| Net interest income | | | | | 0.0 | | | |
| Revenue growth [+] | 5.1% | 15.1% | -24.3% | -3.0% | 44.8% | 0.4% | -6.3% | -5.7% |
| Custom products | | | | -11.4% | 66.5% | 6.3% | | |
| Medical | | | | 2.3% | 33.7% | -2.3% | | |
| Cost of goods sold | 45.3 | 42.7 | 37.1 | 50.3 | 52.6 | 34.4 | 32.9 | 35.7 |
| Gross profit | 22.3 | 21.6 | 18.8 | 23.6 | 23.5 | 18.1 | 19.4 | 20.2 |
| Gross margin | 32.9% | 33.6% | 33.6% | 31.9% | 30.9% | 34.5% | 37.1% | 36.2% |
| Selling, general and administrative [+] | 15.1 | 15.2 | 14.1 | 15.0 | 14.9 | 12.0 | 11.7 | 12.5 |
| Sales and marketing | 10.5 | 10.8 | 10.1 | 10.7 | 10.4 | 8.7 | 8.7 | 9.0 |
| General and administrative | 4.6 | 4.5 | 4.0 | 4.3 | 4.5 | 3.3 | 3.1 | 3.4 |
| Research and development | 1.1 | 1.1 | 1.1 | 1.2 | 1.1 | 0.6 | 0.9 | 0.9 |
| EBITDA [+] | 7.3 | 6.5 | 4.9 | 8.6 | 8.7 | 6.3 | 7.5 | 7.7 |
| EBITDA growth | 12.1% | 32.3% | -42.9% | -1.6% | 38.7% | -16.7% | -2.2% | -6.4% |
| EBITDA margin | 10.7% | 10.1% | 8.8% | 11.6% | 11.5% | 12.0% | 14.4% | 13.8% |
| Depreciation | 0.9 | 0.9 | 0.9 | 0.8 | 0.8 | 0.7 | 0.7 | 0.8 |
| EBITA | 6.4 | 5.6 | 4.0 | 7.8 | 7.9 | 5.5 | 6.8 | 7.0 |
| EBITA margin | 9.4% | 8.7% | 7.2% | 10.5% | 10.4% | 10.5% | 13.0% | 12.4% |
| Amortization of intangibles | 0.3 | 0.3 | 0.4 | 0.5 | 0.4 | 0.1 | 0.1 | 0.1 |
| EBIT [+] | 6.1 | 5.3 | 3.6 | 7.3 | 7.5 | 5.5 | 6.7 | 6.9 |
| EBIT growth | 15.7% | 45.6% | -50.5% | -2.9% | 37.2% | -18.7% | -1.9% | -8.7% |
| EBIT margin | 9.0% | 8.2% | 6.5% | 9.9% | 9.9% | 10.4% | 12.9% | 12.3% |
| Interest income, net [+] | 0.0 | 0.0 | 0.0 | 0.0 | | | 0.1 | 0.0 |
| Interest expense | 0.0 | 0.0 | 0.0 | 0.0 | | | | 0.0 |
| Interest income | | | | | | | 0.1 | 0.0 |
| Other income (expense), net [+] | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | | |
| Gain (loss) on foreign currency transactions | 0.0 | 0.4 | 0.0 | 0.0 | -0.3 | | | |
| Other | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
| Pre-tax income | 6.1 | 5.7 | 3.6 | 7.3 | 7.5 | 5.5 | 6.8 | 6.9 |
| Income taxes | 1.8 | 1.7 | 1.0 | 2.2 | 2.3 | 1.8 | 2.3 | 2.2 |
| Tax rate | 30.1% | 29.5% | 28.6% | 30.4% | 30.2% | 32.7% | 33.6% | 31.7% |
| Net income | 4.2 | 4.0 | 2.6 | 5.1 | 5.2 | 3.7 | 4.5 | 4.7 |
| Net margin | 6.3% | 6.2% | 4.6% | 6.9% | 6.8% | 7.0% | 8.6% | 8.4% |
| |
| Basic EPS [+] | $1.55 | $1.34 | $0.88 | $1.72 | $1.80 | $1.33 | $1.65 | $1.72 |
| Growth | 15.8% | 52.6% | -49.0% | -4.4% | 35.4% | -19.1% | -4.5% | -1.9% |
| Diluted EPS [+] | $1.54 | $1.33 | $0.87 | $1.69 | $1.77 | $1.30 | $1.59 | $1.68 |
| Growth | 15.9% | 53.5% | -48.9% | -4.4% | 35.8% | -17.9% | -5.5% | -1.1% |
| |
| Dividends per share [+] | $0.64 | $1.61 | $0.57 | $1.52 | $0.47 | $0.42 | $1.40 | $0.36 |
| Growth | -60.2% | 182.5% | -62.4% | 222.3% | 11.9% | -70.0% | 288.9% | 5.9% |
| |
| Shares outstanding (basic) [+] | 2.7 | 3.0 | 2.9 | 2.9 | 2.9 | 2.8 | 2.7 | 2.7 |
| Growth | -8.2% | 1.0% | 0.3% | 1.6% | 4.1% | 1.5% | 0.3% | -1.5% |
| Shares outstanding (diluted) [+] | 2.8 | 3.0 | 3.0 | 3.0 | 2.9 | 2.8 | 2.8 | 2.8 |
| Growth | -8.2% | 0.4% | 0.0% | 1.6% | 3.8% | -0.1% | 1.3% | -2.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|